{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:41:32Z","timestamp":1790106092479,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.mayocp.2019.08.021","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:12:53Z","timestamp":1571299973000},"page":"77-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies"],"prefix":"10.1016","volume":"95","author":[{"given":"R. Scott","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-9087","authenticated-orcid":false,"given":"Michael G.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Stoekenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.J.","family":"Wijngaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kallend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2019.08.021_bib1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"10159","key":"10.1016\/j.mayocp.2019.08.021_bib2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"issue":"25 Pt B","key":"10.1016\/j.mayocp.2019.08.021_bib3","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.08.021_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A\u00a0century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"9841","key":"10.1016\/j.mayocp.2019.08.021_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.mayocp.2019.08.021_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"8934","key":"10.1016\/j.mayocp.2019.08.021_bib7","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.mayocp.2019.08.021_bib8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"9326","key":"10.1016\/j.mayocp.2019.08.021_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.mayocp.2019.08.021_bib10","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2019.08.021_bib11","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2019.08.021_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-med-042716-091351","article-title":"PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes","volume":"69","author":"Hess","year":"2018","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1016\/j.mayocp.2019.08.021_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2019.08.021_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2019.08.021_bib15","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2019.08.021_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2019.08.021_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2019.08.021_bib18","unstructured":"K.K. Ray. Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1. Paper presented at: European Society of Cardiology (ESC) Congress 2017; August 26-30, 2017; Barcelona, Spain. FP Number\u00a03064."},{"key":"10.1016\/j.mayocp.2019.08.021_bib19","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.mayocp.2019.08.021_bib20","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.mayocp.2019.08.021_bib21","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.mayocp.2019.08.021_bib22","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.mayocp.2019.08.021_bib23","series-title":"Data on File","year":"2019"},{"issue":"7","key":"10.1016\/j.mayocp.2019.08.021_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction: a high-risk combination","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mayocp.2019.08.021_bib25","doi-asserted-by":"crossref","first-page":"767424","DOI":"10.1155\/2014\/767424","article-title":"An update on coronary artery disease and chronic kidney disease","volume":"2014","author":"Afsar","year":"2014","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.mayocp.2019.08.021_bib26","author":"Del Vecchio"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619307566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619307566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:32:47Z","timestamp":1758418367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619307566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0025619619307566"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.08.021","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}